A Phase 1/2 interventional study of Biopsy Procedure and Biospecimen Collection in Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 22 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.
Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 5 that started in 2019, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 10 other live ones, and was the 8th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zin W Myint · Sites in United States
Ages 18+ · Men only
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 25 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
202 studies in Prostatic Neoplasms by National Cancer Institute (NCI): 26 open now, 43 under way, none of them phase 3. Of 154 finished, 84 (55%) have results posted.
Among the 202 studies in Prostatic Neoplasms by National Cancer Institute (NCI), this one is the 17th largest by enrollment of the 166 interventional ones that give a count, is one of 9 that started in 2019, is one of 16 in phase 1/2, reaches primary completion later than 5 of the 37 other live ones, and was the 155th registered.
National Cancer Institute (NCI)’s Prostatic Neoplasms studies by the year they started, since 1988.
2 of the studies testing olaparib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04038502VA Office of Research and DevelopmentCarboplatin or Olaparib for BRcA Deficient Prostate Cancer | 2027-08-31 |
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies testing olaparib in Prostatic Neoplasms, from their registry updates:
Among National Cancer Institute (NCI)’s 202 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may help treat patients with castration-resistant prostate cancer.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I) II. Evaluate the radiographic progression-free survival (rPFS). (Phase II)
SECONDARY OBJECTIVES:
I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
II. To evaluate rPFS as stratified by disease extent (=\< 20 or > 20 bone lesions) and prior docetaxel use (yes or no).
III. Evaluate rPFS in patients harboring or lacking evidence of homologous recombination deficiency (HRD).
IV. Evaluate rPFS in patients based on prior abiraterone and/or next generation androgen receptor (AR) antagonist (enzalutamide, apalutamide, darolutamide or other agent) use (yes versus no) for either hormone sensitive or castration resistant prostate cancer (CRPC).
V. Evaluate prostate specific antigen (PSA) response rate as defined by >= 50% decline in PSA from baseline.
VI. Evaluate total alkaline phosphatase response defined as a reduction of >= 30% from the baseline value, confirmed >= 4 weeks later.
VII. Evaluate time to PSA progression as defined by Prostate Cancer Clinical Trials Working Group (PCTWG) 3 criteria.
VIII. Evaluate radiographic objective response rate as defined by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.
IX. Evaluate time to increase in the total alkaline phosphatase (ALP) level defined as an increase of >= 25% from baseline at >= 12 weeks, in patients with no decrease from baseline, or as an increase of >= 25% above the nadir, confirmed >= 3 weeks later, in patients with an initial decrease from baseline.
X. Evaluate time to first subsequent anti-cancer therapy (including AR signaling agents, cytotoxic chemotherapy, immunotherapy, or investigational agents) or death.
XI. Evaluate time to first symptomatic skeletal event (SSE). XII. Evaluate overall survival (OS).
EXPLORATORY OBJECTIVES:
I. Evaluate impact on quality of life (QOL) as determined by Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI).
II. Estimate the frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway in patients with metastatic castration-resistant prostate cancer (CRPC) as determine by Oncopanel testing and by whole exome sequencing (WES).
III. Characterize changes in ribonucleic acid (RNA) expression of DNA repair genes and immune markers by whole transcriptome sequencing (WTS) in each arm.
IV. Characterize changes in immune cell, T-cell receptor (TCR), and B-cell (BCR) receptor repertoire at baseline, during treatment, and at progression in each arm.
V. Evaluate changes in lactate dehydrogenase (LDH) in patients each treatment arm.
VI. Assess the prevalence of germline mutations in homologous recombination genes in all enrolled patients.
VII. Correlate homologous recombination gene germline mutation status with PSA response by treatment arm.
VIII. Evaluate family history of cancers in the study population and correlate family cancer history with germline mutation status.
IX. Correlate presence or absence of RAD51 with somatic and germline homologous recombination gene mutation status, PSA response, and PFS between treatment arms.
X. Evaluate the changes in whole genome sequencing (WGS) of plasma cell-free circulating DNA (cfDNA) based patient-tumor specific signature at baseline, on treatment, and at progression.
XI. Evaluate tumor mutation burden (TMB) and tumor mutational signature in plasma cfDNA at baseline and correlate to tumor tissue TMB and mutational signature.
OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.
PHASE I: Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) as well as blood sample collection and a tissue biopsy during screening and on study.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
ARM II: Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
After completion of study treatment, patients are followed up every 6 months for 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have progressive disease as defined by any of the following:
Participants should be receiving an osteoclast targeting agent including either bisphosphonates or denosumab except in patients with as determined by the treating investigator including:
Exclusion Criteria:
medical condition defined as:
Individuals with a history of a different are ineligible except for the following circumstances:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in Phase I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride
Patients in Phase II Arm I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride
Patients in Phase 2 Arm II receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride
Undergo tissue biopsy
Also known as: Biopsy, BIOPSY_TYPE, Bx
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo CT
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Correlative studies
Undergo MRI
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Given PO
Also known as: AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
Ancillary studies
Also known as: Quality of Life Assessment
Given IV
Also known as: Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo
Phase I: Maximum Tolerated Dose
Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I)
Time frame: 56 days
Phase II: Radiographic Progression-free Survival (rPFS)
Radiographic progression is defined by Prostate Cancer Working Group 3 criteria for bone metastases and RECIST version 1.1 for non-bone metastases. Median rPFS will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",
Time frame: From randomization to date of radiographic progression or death due to any cause, whichever occurs first, or censored at the date of last disease assessment. Up to approximately 2 years
Phase II: rPFS in Patients Without Prior Docetaxel
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
Time frame: Up to approximately 2 years after randomization
Phase II: rPFS in Patients With Prior Docetaxel
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
Time frame: Up to approximately 2 years after randomization
Phase II: rPFS in Patients With ≤ 20 Bone Lesions
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
Time frame: Up to approximately 2 years after randomization
Phase II: rPFS in Patients With > 20 Bone Lesions
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
Time frame: Up to approximately 2 years after randomization
Phase II: Overall Survival (OS)
Phase II: Median OS will be estimated using the method of Kaplan-Meier.
Time frame: From randomization to the date of death due to any cause, or censored at the date of last follow-up, assessed up to 3.5 years
Phase II: rPFS in Patients Without Homologous Recombination Deficiency
rPFS in patients without homologous recombination deficiency
Time frame: Up to approximately 2 years after randomization
Phase II: rPFS in Patients With Homologous Recombination Deficiency
rPFS in patients with homologous recombination deficiency
Time frame: Up to approximately 2 years after randomization
Phase II: Prostate Specific Antigen (PSA) Response
Number of participants with prostate specific antigen (PSA) response defined as PSA ≥50% decrease from baseline
Time frame: Up to approximately 2 years after randomization
Phase II: Alkaline Phosphatase (ALP) Response
Alkaline phosphatase (ALP) response defined as ≥30% decrease from baseline.
Time frame: Up to approximately 2 years after randomization
Phase II: Symptomatic Skeletal Event (SSE)
Symptomatic skeletal event (SSE) defined as pathologic bone fracture, spinal cord compression, or radiation therapy to bone.
Time frame: Up to approximately 2 years after randomization
Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)
Incidence of grade 3 or higher treatment related adverse events (TrAE)
Time frame: Up to approximately 2 years after randomization
| Milestone | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|---|---|
| Started | 6 | 6 | 61 | 59 |
| Completed | 6 | 6 | 59 | 55 |
| Not completed | 0 | 0 | 2 | 4 |
| Withdrew: Did not receive study therapy | 0 | 0 | 2 | 4 |
Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I)
| mg | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 |
|---|---|---|
| Phase I: Maximum Tolerated Dose | 200 | 200 |
Radiographic progression is defined by Prostate Cancer Working Group 3 criteria for bone metastases and RECIST version 1.1 for non-bone metastases. Median rPFS will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Radiographic Progression-free Survival (rPFS) | 8.9 (5.4 to 13.7) | 4.7 (3.2 to 6.0) |
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients Without Prior Docetaxel | 13.7 (11.3 to 17.2) | 5.7 (3.3 to 8.3) |
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients With Prior Docetaxel | 6.6 (3.3 to 8.9) | 3.3 (2.9 to 5.6) |
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients With ≤ 20 Bone Lesions | 13.4 (11.3 to 17.0) | 4.1 (2.9 to 5.7) |
Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients With > 20 Bone Lesions | 4.7 (3.1 to 8.8) | 4.8 (3.1 to 11.0) |
Phase II: Median OS will be estimated using the method of Kaplan-Meier.
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Overall Survival (OS) | 20.2 (13.8 to 25.7) | 21.1 (14.4 to 23.7) |
rPFS in patients without homologous recombination deficiency
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients Without Homologous Recombination Deficiency | 5.7 (3.1 to 15.8) | 5.6 (3.3 to 11.0) |
rPFS in patients with homologous recombination deficiency
| months | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: rPFS in Patients With Homologous Recombination Deficiency | 13.9 (4.7 to 99) | 3.0 (2.9 to 10.0) |
Number of participants with prostate specific antigen (PSA) response defined as PSA ≥50% decrease from baseline
| Participants | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Prostate Specific Antigen (PSA) Response | 9 | 9 |
Alkaline phosphatase (ALP) response defined as ≥30% decrease from baseline.
| Participants | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Alkaline Phosphatase (ALP) Response | 30 | 30 |
Symptomatic skeletal event (SSE) defined as pathologic bone fracture, spinal cord compression, or radiation therapy to bone.
| Percent of participants | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Symptomatic Skeletal Event (SSE) | 12.7 (4.9 to 24.2) | 22.9 (9.5 to 39.7) |
Incidence of grade 3 or higher treatment related adverse events (TrAE)
| events | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) |
|---|---|---|
| Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE) | 44 | 23 |
Collected over Adverse events (AE) are assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5 by treatment arm, from enrollment until end of study visit, up to approximately 2.5 years after randomization. All-Cause Mortality monitored/assessed up to 3.5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I Radium223+Olaparib Dose Level 1 | 6/6 (100%) | 4/6 (66.7%) | 6/6 (100%) |
| Phase I Radium223+Olaparib Dose Level 2 | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | 38/61 (62.3%) | 39/59 (66.1%) | 59/59 (100%) |
| Phase II Arm II (Radium Ra 223 Dichloride) | 18/59 (30.5%) | 29/55 (52.7%) | 55/55 (100%) |
| Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib) | 16/23 (69.6%) | 11/23 (47.8%) | 23/23 (100%) |
| Event | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib) |
|---|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 0/6 | 2/6 | 18/59 | 8/55 | 6/23 |
| AnemiaBlood and lymphatic system disorders | 2/6 | 1/6 | 13/59 | 10/55 | 2/23 |
| Platelet count decreasedInvestigations | 1/6 | 0/6 | 5/59 | 3/55 | 0/23 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 | 1/59 | 3/55 | 2/23 |
| HematuriaRenal and urinary disorders | 1/6 | 0/6 | 1/59 | 1/55 | 0/23 |
| Lung infectionInfections and infestations | 1/6 | 0/6 | 1/59 | 0/55 | 0/23 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/59 | 0/55 | 0/23 |
| HypertensionVascular disorders | 0/6 | 0/6 | 4/59 | 3/55 | 0/23 |
| White blood cell decreasedInvestigations | 0/6 | 0/6 | 4/59 | 1/55 | 1/23 |
| Neutrophil count decreasedInvestigations | 0/6 | 0/6 | 3/59 | 3/55 | 1/23 |
| Event | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib) |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 6/6 | 5/6 | 40/59 | 28/55 | 6/23 |
| AnemiaBlood and lymphatic system disorders | 3/6 | 4/6 | 44/59 | 32/55 | 14/23 |
| Lymphocyte count decreasedInvestigations | 0/6 | 4/6 | 33/59 | 27/55 | 13/23 |
| White blood cell decreasedInvestigations | 0/6 | 4/6 | 31/59 | 27/55 | 10/23 |
| NauseaGastrointestinal disorders | 3/6 | 3/6 | 30/59 | 21/55 | 8/23 |
| DiarrheaGastrointestinal disorders | 3/6 | 2/6 | 28/59 | 22/55 | 6/23 |
| PainGeneral disorders | 3/6 | 1/6 | 14/59 | 10/55 | 7/23 |
| AnorexiaMetabolism and nutrition disorders | 2/6 | 2/6 | 19/59 | 21/55 | 9/23 |
| HyperglycemiaMetabolism and nutrition disorders | 0/6 | 1/6 | 12/59 | 15/55 | 9/23 |
| Blood lactate dehydrogenase increasedInvestigations | 1/6 | 1/6 | 13/59 | 8/55 | 9/23 |
| Age, Continuous(years) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| Median | 67 (64 to 73) | 68 (66 to 69) | 69 (63 to 77) | 71 (66 to 76) | 70 (65 to 76) |
| Sex: Female, Male(Participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 61 | 59 | 132 |
| Race (NIH/OMB)(Participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 6 | 9 |
| White | 6 | 5 | 53 | 50 | 114 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 3 | 3 | 7 |
| Region of Enrollment(participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| United States | 6 | 6 | 61 | 59 | 132 |
| Previous use of androgen receptor pathway inhibitors(Participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| Count of participants | 6 | 6 | 59 | 56 | 127 |
| Previous use of any chemotherapy(Participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| Count of participants | 2 | 1 | 34 | 30 | 67 |
| Previous use of docetaxel(Participants) | Phase I Radium223+Olaparib Dose Level 1 | Phase I Radium223+Olaparib Dose Level 2 | Phase II Arm I (Radium Ra 223 Dichloride, Olaparib) | Phase II Arm II (Radium Ra 223 Dichloride) | Total |
|---|---|---|---|---|---|
| Count of participants | 2 | 1 | 32 | 30 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Ran from Feb 2019 to primary completion in Mar 2025, 73 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's 73 months is above that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib
National Cancer Institute (NCI) →